At UOVO®, we have designed a unique functional model for the process of creating high-impact companies. It is an operational model that institutionalizes the process of ideation, formulation, and execution of high-potential projects, reducing the risk of failure and optimizing investment.
To achieve this, Uovo has developed internal processes over two years that not only support its success in diagnosing the needs of the Argentine scientific ecosystem but also optimizes the virtues of the context aimed at generating value. It brings together state-of-the-art technology previously unavailable in our country with a process of generating initiatives that are iteratively executed and refined, making efficient use of installed capacity, talent, and industrial experience, as well as knowledge for the internationalization of developed solutions. Uovo combines experience in the biotechnology field, capital, and entrepreneurial culture to launch high-impact projects, thus increasing success and reducing maturity times.
The McKinsey 2020 "BIOREVOLUTION" report presents compelling data for the economy of the future (2030-2040): 60% of the goods in the global economy can be solved biologically, 45% of diseases can be solved through biotechnology, and 45% of private R&D spending will correspond to biotechnology innovation activities. Sustralys, Pepton, Rescience, Bioadvance, Houndee, MyBiot, and Bioseek are the first examples of companies created at Uovo from their own ideas, working on solutions to the current and coming challenges of society (food, energy, health, and the environment). As we look towards the future, we are confident that biotechnology innovation will play a significant role in solving global challenges, and we are well-positioned to be at the forefront of this revolution.
To achieve this, Uovo has developed internal processes over two years that not only support its success in diagnosing the needs of the Argentine scientific ecosystem but also optimizes the virtues of the context aimed at generating value. It brings together state-of-the-art technology previously unavailable in our country with a process of generating initiatives that are iteratively executed and refined, making efficient use of installed capacity, talent, and industrial experience, as well as knowledge for the internationalization of developed solutions. Uovo combines experience in the biotechnology field, capital, and entrepreneurial culture to launch high-impact projects, thus increasing success and reducing maturity times.
The McKinsey 2020 "BIOREVOLUTION" report presents compelling data for the economy of the future (2030-2040): 60% of the goods in the global economy can be solved biologically, 45% of diseases can be solved through biotechnology, and 45% of private R&D spending will correspond to biotechnology innovation activities. Sustralys, Pepton, Rescience, Bioadvance, Houndee, MyBiot, and Bioseek are the first examples of companies created at Uovo from their own ideas, working on solutions to the current and coming challenges of society (food, energy, health, and the environment). As we look towards the future, we are confident that biotechnology innovation will play a significant role in solving global challenges, and we are well-positioned to be at the forefront of this revolution.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
